Last reviewed · How we verify
NCT06251232: DILICORT
Proof-of-concept to Evaluate the Efficacy and Safety of Prednisone in Idiosyncratic Hepatotoxicity
Phase 2 trial testing Prednisone in Hepatotoxicity in 60 participants. Not yet recruiting.
31 December 2027
Quick facts
| Lead sponsor | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 May 2024 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2028 |
Drugs / interventions tested
- Prednisone (prednisone) — full drug profile →
Conditions studied
- Hepatotoxicity — all drugs for Hepatotoxicity →
- Idiosyncratic Drug Effect — all drugs for Idiosyncratic Drug Effect →
- Prednisone — all drugs for Prednisone →
Sponsor
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud — full company profile →
Who can join
18 and older, any sex, with Hepatotoxicity or Idiosyncratic Drug Effect. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial´s aim is to assess if oral prednisone (compared to placebo), administered over five weeks is beneficial in terms of decreased total bilirubin (TBL): reduction of the peak of TBL at least 50% at 14 days or reduction in the time to normalisation of TBL value.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06251232
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Prednisone
Trials testing the same drug.
- NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
- NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
- NCT06738368 — Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombin · Phase 2 · recruiting
- NCT07493148 — Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL · Phase 2 · recruiting
- NCT07278856 — Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphoma · Phase 1 · not yet recruiting
Other recruiting trials for Hepatotoxicity
Currently open trials in the same condition.
- NCT05501899 — Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
- NCT04635111 — A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment · recruiting
Other Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud trials
Trials by the same sponsor.
- NCT06852014 — Effects of Peptamen 1.6 in Malnourished Patients (or at Risk) With Pancreatic Neoplasia Undergoing Cephalic Pancreaticod · NA · recruiting
- NCT06936501 — The Cooling Sensation Safe Deglution Study · NA · recruiting
- NCT07192445 — Usability of Graphic Medicine in Psychology Education · NA · completed
- NCT06558526 — Pectin Intervention Study and Long-term Follow-up in Lipid Transfer Proteins Allergic Patients · NA · recruiting
- NCT06040164 — Oral Endocannabinoids in People With Prediabetes and Diabetes · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06251232 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
- Last refreshed: 5 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06251232.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing